Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07793942
Starting soon Phase 2

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

NCT07793942 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Started
2026-10-27
Last updated
2026-10-08

Condition(s) studied

Malignant NeoplamAdvanced Solid Tumors

Investigational drug(s) / intervention(s)

MK-2010 →Pembrolizumab →5-Fluorouracil →Leucovorin or Levoleucovorin →Oxaliplatin →Belzutifan →Gemcitabine →Cisplatin →Carboplatin →Paclitaxel →Nab-paclitaxel →Pemetrexed →Epinephrine →

MK-2010: Administered as an intravenous (IV) infusion.

Pembrolizumab: Administered intravenously as 400 mg every 6 weeks.

5-Fluorouracil: Administered intravenously per approved product label.

Leucovorin or Levoleucovorin: Administered intravenously per approved product label.

Oxaliplatin: Administered intravenously per approved product label.

Belzutifan: Administered orally as 120 mg daily.

Gemcitabine: Administered intravenously per approved product label.

Cisplatin: Administered intravenously per approved product label.

Carboplatin: Administered intravenously per approved product label.

Paclitaxel: Administered intravenously per approved product label.

Nab-paclitaxel: Administered intravenously per approved product label.

Pemetrexed: Administered intravenously per approved product label.

Epinephrine: Administered per approved product label as rescue medication.

Study summary

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery.

In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer.

The goals of this trial are to learn:

* About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems.
* How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Has radiographically measurable disease per protocol * If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption * Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV * Has adequate organ function per protocol Exclusion Criteria: * Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV * Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder * Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis * Has a history of confirmed inflammatory bowel disease * Has a serious active nonhealing wound, ulcer, and/or bone fracture * Has a history of myocarditis or cardiomyopathy * Has a history of or current severe cardiovascular and cerebrovascular diseases * Is currently receiving any anticoagulants * Has a diagnosis of immunodeficiency * Has a known additional malignancy that is progressing or required active treatment within the past 3 years * Has known active central nervous system metastases and/or carcinomatous meningitis * Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed) * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD * Has a history of stem cell/solid organ transplant * Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications

Primary outcome measure(s)

  • Number of Participants with Adverse Events (AEs) — Up to approximately 24 months
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
  • Number of Participants Who Discontinue Study Treatment Due to an AE — Up to approximately 24 months
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
  • Number of Participants Who Experience Dose-Limiting Toxicity (DLT) — Up to approximately 28 days
    DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next dose.
  • Objective Response Rate (ORR) — Up to approximately 24 months
    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Trial sites (6)

FacilityCityRegionStatus
New Jersey Cancer Care ( Site 7002) Belleville New Jersey
START Astera, LLC ( Site 0220) East Brunswick New Jersey
Taylor Cancer Research Center ( Site 9500) Maumee Ohio
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001) Eugene Oregon
Cantonal Hospital St.Gallen ( Site 1100) Sankt Gallen Canton of St. Gallen
CHUV (centre hospitalier universitaire vaudois) ( Site 1101) Lausanne Canton of Vaud

On this site

📄 Keytruda (pembrolizumab) drug profile →

More Merck Sharp & Dohme LLC trials in Switzerland

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Active, not recruiting
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Active, not recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) Recruiting

Other trials for the same condition

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Active, not recruiting
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments Active, not recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Active, not recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Recruiting
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07793942 on ClinicalTrials.gov ↗ ← All trials in Switzerland